HVTN Protocol 204 - A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRCHIVADV014-00-VP, in HIV-1 Uninfected Adult Participants

NCT00125970 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

480

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: VRC-HIVDNA016-00-VP
BIOLOGICAL: VRC-HIVADV014-00-VP
BIOLOGICAL: VRC-HIVDNA016-00-VP placebo
BIOLOGICAL: VRC-HIVADV014-00-VP placebo

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)